amrinone has been researched along with Coronary Heart Disease in 23 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hemodynamic measurements were done in 42 patients with congestive heart failure of NYHA classes III and IV after administration of the phosphodiesterase inhibitors amrinone und enoximone." | 9.07 | [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]. ( Peters, P; Saborowski, F; Schneider, M, 1991) |
| "The effects of intravenous amrinone and sodium nitroprusside on haemodynamic indices, left ventricular contractility, and myocardial metabolism were compared in patients with cardiac failure." | 7.67 | Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. ( Coltart, DJ; Jenkins, BS; Juul, SM; Thompson, DS; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "The acute effects of an oral preparation of amrinone, a recently synthesized cardiotonic agent, were assessed noninvasively in nine patients who had advanced heart failure that persisted despite treatment with digitalis, diuretic drugs and afterload-reducing agents." | 7.66 | Oral amrinone in refractory congestive heart failure. ( Benotti, JR; Braunwald, E; Curfman, GD; Grossman, W; Holman, BL; Malacoff, RF; Smith, TW; Wynne, J, 1980) |
| "Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown." | 7.66 | Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. ( Benotti, JR; Braunwald, E; Carabello, BA; Grossman, W, 1980) |
| "Hemodynamic measurements were done in 42 patients with congestive heart failure of NYHA classes III and IV after administration of the phosphodiesterase inhibitors amrinone und enoximone." | 5.07 | [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]. ( Peters, P; Saborowski, F; Schneider, M, 1991) |
| "The effects of intravenous amrinone and sodium nitroprusside on haemodynamic indices, left ventricular contractility, and myocardial metabolism were compared in patients with cardiac failure." | 3.67 | Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. ( Coltart, DJ; Jenkins, BS; Juul, SM; Thompson, DS; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "The purpose of the present study was to induce left ventricular failure in anesthetized dogs by repeated ventricular fibrillation and then to determine if amrinone is effective in circulatory support by comparing the effects of amrinone and dobutamine." | 3.67 | Comparison of the effects of amrinone and dobutamine on hemodynamics and myocardial oxygen balance in dogs with experimental left ventricular failure. ( Fujigaki, T; Fukui, S; Gotoh, Y; Haseba, S; Miyako, M; Nakamura, H, 1989) |
| "The acute effects of an oral preparation of amrinone, a recently synthesized cardiotonic agent, were assessed noninvasively in nine patients who had advanced heart failure that persisted despite treatment with digitalis, diuretic drugs and afterload-reducing agents." | 3.66 | Oral amrinone in refractory congestive heart failure. ( Benotti, JR; Braunwald, E; Curfman, GD; Grossman, W; Holman, BL; Malacoff, RF; Smith, TW; Wynne, J, 1980) |
| "Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown." | 3.66 | Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. ( Benotti, JR; Braunwald, E; Carabello, BA; Grossman, W, 1980) |
| "In amrinone treated patients bolus dose of amrinone 1." | 2.68 | [Effects of amrinone on oxygen demand-supply relationship after cardiopulmonary bypass in patient undergoing coronary bypass surgery]. ( Furuya, H; Kaneko, M; Kawaguchi, M; Kitaguchi, K; Nishimura, K; Sakamoto, T; Sha, K; Shimokawa, M, 1997) |
| "Amrinone is a potent alternative which combines positive inotropic and vasodilating properties." | 2.38 | [The treatment of heart insufficiency in coronary heart disease]. ( Bertel, O; Gerber, A, 1991) |
| "Amrinone led to a 23% increase in cardiac index resulting mainly from reduction in afterload." | 1.29 | Effects of amrinone on left and right ventricular function in patients with impaired myocardial performance during general anaesthesia. ( Dütschke, P; Petry, A, 1994) |
| "Amrinone is an inotropic agent that does not critically augment myocardial oxygen demand and may be useful for identification of hibernating myocardium in the chronically ischemic state." | 1.29 | Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function. ( Boullon, F; Brown, KA; Cragnolino, DE; Masoli, OH; Mele, E; Meretta, AH; Palacios, I; Perez-Baliño, NA; Perrone, S; Rodriguez, A, 1996) |
| "Amrinone is an effective vasodilator without altering systolic and mean arterial blood pressure or heart rate strongly." | 1.27 | [Peripheral hemodynamics and metabolic parameters influenced by amrinone at rest and following handgrip stress]. ( Griebenow, R; Peters, P; Saborowski, F, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (47.83) | 18.7374 |
| 1990's | 12 (52.17) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilmshurst, PT | 1 |
| Thompson, DS | 1 |
| Juul, SM | 1 |
| Jenkins, BS | 1 |
| Coltart, DJ | 1 |
| Webb-Peploe, MM | 1 |
| Wynne, J | 1 |
| Malacoff, RF | 1 |
| Benotti, JR | 2 |
| Curfman, GD | 1 |
| Grossman, W | 2 |
| Holman, BL | 1 |
| Smith, TW | 1 |
| Braunwald, E | 2 |
| Carabello, BA | 1 |
| Günnicker, M | 1 |
| Brinkmann, M | 1 |
| Donovan, TJ | 1 |
| Freund, U | 1 |
| Schieffer, M | 1 |
| Reidemeister, JC | 1 |
| Massardo, T | 2 |
| González, P | 2 |
| Yovanovich, J | 1 |
| Maiers, E | 2 |
| Ayala, F | 2 |
| Ramírez, A | 2 |
| Berr, JL | 1 |
| Zamorano, J | 2 |
| Humeres, P | 1 |
| Muñoz, A | 1 |
| Berr, ML | 1 |
| Arriagada, M | 1 |
| Alliende, I | 1 |
| Petry, A | 1 |
| Dütschke, P | 1 |
| Tateyama, T | 1 |
| Suzuki, H | 1 |
| Fukuyama, H | 1 |
| Fujiwara, R | 1 |
| Abe, Y | 1 |
| Okutsu, Y | 1 |
| Perez-Baliño, NA | 1 |
| Masoli, OH | 1 |
| Meretta, AH | 1 |
| Rodriguez, A | 1 |
| Cragnolino, DE | 1 |
| Perrone, S | 1 |
| Boullon, F | 1 |
| Mele, E | 1 |
| Palacios, I | 1 |
| Brown, KA | 1 |
| Sha, K | 1 |
| Shimokawa, M | 1 |
| Kawaguchi, M | 1 |
| Sakamoto, T | 1 |
| Nishimura, K | 1 |
| Kaneko, M | 1 |
| Kitaguchi, K | 1 |
| Furuya, H | 1 |
| Saborowski, F | 3 |
| Griebenow, R | 2 |
| Lessing, P | 1 |
| Peters, P | 2 |
| Schneider, M | 1 |
| Whitten, CW | 1 |
| Latson, TW | 1 |
| Klein, KW | 1 |
| Elmore, J | 1 |
| Spencer, R | 1 |
| Duggar, P | 1 |
| Bertel, O | 1 |
| Gerber, A | 1 |
| Zucchi, R | 1 |
| Poddighe, R | 1 |
| Mariani, M | 1 |
| Ronca, G | 1 |
| Fujigaki, T | 2 |
| Nakamura, H | 1 |
| Fukui, S | 1 |
| Miyako, M | 1 |
| Haseba, S | 1 |
| Gotoh, Y | 1 |
| Bradley, AB | 1 |
| Baim, DS | 1 |
| Rutman, HI | 1 |
| LeJemtel, TH | 1 |
| Sonnenblick, EH | 1 |
| Löwe, H | 1 |
| Schulz, U | 1 |
| Blasig, IE | 1 |
| Lukas, A | 1 |
| Ferrier, GR | 1 |
| Klepzig, M | 1 |
| Kleinhans, E | 1 |
| Büll, U | 1 |
| Strauer, BE | 1 |
4 reviews available for amrinone and Coronary Heart Disease
| Article | Year |
|---|---|
Anesthetic management of a hypothyroid cardiac surgical patient.
Topics: Amrinone; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intravenous; Aortic Valve; Aortic | 1991 |
[The treatment of heart insufficiency in coronary heart disease].
Topics: Amrinone; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Bypass; Coronary Di | 1991 |
Measurement of coronary blood flow in man: methods and implications for clinical practice.
Topics: Amrinone; Angina Pectoris; Animals; Cardiomegaly; Coronary Circulation; Coronary Disease; Coronary V | 1985 |
Newer cardiotonic agents: implications for patients with heart failure and ischemic heart disease.
Topics: Amrinone; Cardiotonic Agents; Coronary Disease; Heart Failure; Humans; Phosphodiesterase Inhibitors; | 1987 |
4 trials available for amrinone and Coronary Heart Disease
| Article | Year |
|---|---|
The efficacy of amrinone or adrenaline on low cardiac output following cardiopulmonary bypass in patients with coronary artery disease undergoing preoperative beta-blockade.
Topics: Adrenergic beta-Antagonists; Amrinone; Cardiac Output, Low; Cardiopulmonary Bypass; Cardiotonic Agen | 1995 |
[Evaluation of coronary revascularization: comparison between perfusion with dipyridamole Tc99m sestaMIBI and amrinone-echocardiography as predictors of viability].
Topics: Adult; Aged; Amrinone; Coronary Disease; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial | 1994 |
[Effects of amrinone on oxygen demand-supply relationship after cardiopulmonary bypass in patient undergoing coronary bypass surgery].
Topics: Amrinone; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Disease; Hemodynamics; Humans; Ox | 1997 |
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
Topics: Aged; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; | 1991 |
15 other studies available for amrinone and Coronary Heart Disease
| Article | Year |
|---|---|
Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.
Topics: Adult; Aminopyridines; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Fema | 1984 |
Oral amrinone in refractory congestive heart failure.
Topics: Aged; Aminopyridines; Amrinone; Blood Pressure; Coronary Disease; Electrocardiography; Female; Heart | 1980 |
Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.
Topics: Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disea | 1980 |
[Tomographic myocardial perfusion (SPECT) using 99mTc sestamibi-dipyridamole and 2-d-echocardiography with amrinone pre and post myocardial revascularization in 2 cases].
Topics: Amrinone; Coronary Angiography; Coronary Disease; Dipyridamole; Echocardiography; Follow-Up Studies; | 1994 |
Effects of amrinone on left and right ventricular function in patients with impaired myocardial performance during general anaesthesia.
Topics: Adult; Aged; Amrinone; Anesthesia, General; Body Surface Area; Cardiac Output; Central Venous Pressu | 1994 |
[Amrinone (50 micrograms.kg-1.min-1) does not impair regional myocardial tissue metabolism during the 40%-decrease of left anterior descending coronary flow].
Topics: Amrinone; Animals; Cardiotonic Agents; Constriction, Pathologic; Coronary Circulation; Coronary Dise | 1996 |
Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function.
Topics: Aged; Aged, 80 and over; Amrinone; Cardiotonic Agents; Coronary Artery Bypass; Coronary Disease; Fem | 1996 |
[Hemodynamics and metabolic parameters after administration of amrinone in patients with coronary heart disease].
Topics: Acid-Base Equilibrium; Amrinone; Blood Glucose; Coronary Disease; Energy Metabolism; Epinephrine; Fa | 1991 |
Effect of amrinone in the working rat heart: influence of ischaemic damage, adenosine and calcium.
Topics: Adenosine; Amrinone; Animals; Calcium; Cardiac Output; Coronary Disease; Heart; Heart Rate; Hypocalc | 1990 |
Comparison of the effects of amrinone and dobutamine on hemodynamics and myocardial oxygen balance in dogs with experimental left ventricular failure.
Topics: Amrinone; Animals; Blood Pressure; Cardiac Output, Low; Coronary Circulation; Coronary Disease; Dobu | 1989 |
[The effects of dopamine and amrinone on myocardial oxygen demand-supply relationship in dogs with coronary artery stenosis].
Topics: Amrinone; Animals; Coronary Disease; Dogs; Dopamine; Heart; Heart Rate; Myocardium; Oxygen | 1989 |
The effect of amrinone on LDH release and perfusion pressure in isolated ischemic rabbit hearts.
Topics: Amrinone; Animals; Blood Pressure; Coronary Disease; Heart; In Vitro Techniques; L-Lactate Dehydroge | 1988 |
Electrophysiological effects of amrinone and milrinone in an isolated canine cardiac tissue model of ischemia and reperfusion.
Topics: Amrinone; Animals; Coronary Disease; Dogs; Electrophysiology; Heart Conduction System; Male; Milrino | 1988 |
[Peripheral hemodynamics and metabolic parameters influenced by amrinone at rest and following handgrip stress].
Topics: Adolescent; Adult; Amrinone; Blood Pressure; Coronary Disease; Energy Metabolism; Epinephrine; Exerc | 1986 |
[Amrinone in acute and long-term therapy].
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronar | 1985 |